home · filing · 0001104659-23-087873
8-K filed August 4, 2023, 7:59 PM ET
ticker GPCR
CIK 0001888886
leadership
confidence high
sentiment positive
materiality 0.40
Appoints Ted Love, M.D. to Board; amends director compensation policy
Structure Therapeutics Inc.
Ted Love, M.D. appointed as Class III director and Chair of Compensation Committee effective August 3, 2023.
Board size reduced to seven directors; Love determined independent under Nasdaq listing standards.
Initial option grant for new non-employee directors increased to 75,000 ordinary shares (25,000 ADSs).
Annual option grant set at 37,500 ordinary shares (12,500 ADSs); post-termination exercise period extended for trust transfers.
Love receives initial grant of 75,000 shares vesting over 36 months plus cash retainers of $45,000 and $10,000.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-08-03
Filed August 4, 2023, 7:59 PM ET
appointed Ted Love, M.D. to the Board, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ted Love, M.D. was appointed as Class III director and Chair of the Compensation Committee at Structure Therapeutics Inc..
Action appointed
Role Class III director and Chair of the Compensation Committee
Exact text from the filing
appointed Ted Love, M.D. to the Board, effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-23-087873
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.